Transcenta Reports Strong Preclinical Results for LIV1-Targeting ADCs in Breast and Prostate Cancers

Transcenta Holding Limited ( (HK:6628) ) has provided an update.

Transcenta Holding Limited has reported new preclinical data for its novel LIV1-targeting antibody-drug conjugate program TST013, including ADC-2 and ADC-3, showing strong anti-tumor activity and favorable tolerability in multiple patient-derived xenograft models. The findings, presented at the 2026 AACR Annual Meeting, underscore differentiated payload-dependent efficacy, with ADC-2 demonstrating robust effects in ER-positive/HER2-negative breast and NSCLC models and ADC-3 achieving sustained tumor suppression in LIV1-high prostate cancer.

The data, alongside earlier results in triple-negative breast cancer, strengthen Transcenta’s case for advancing its LIV1-targeting ADCs into further development for a broad range of LIV1-positive solid tumors. Demonstrated in vivo stability, an extended half-life versus a benchmark analog and a defined maximum tolerated dose for ADC-2 in mice highlight a potentially competitive profile that could enhance the company’s positioning in the emerging ADC oncology segment, while underscoring both the promise and remaining development risks for investors and clinical stakeholders.

More about Transcenta Holding Limited

Transcenta Holding Limited is a biotech company focused on developing antibody-drug conjugates and other biologic therapies targeting solid tumors. Leveraging proprietary antibody platforms and site-specific conjugation technologies, the company is advancing candidates aimed at breast, prostate and lung cancers, with a particular focus on LIV1-positive tumor types.

Average Trading Volume: 1,036,519

Technical Sentiment Signal: Buy

Current Market Cap: HK$1.21B

Find detailed analytics on 6628 stock on TipRanks’ Stock Analysis page.